Related references
Note: Only part of the references are listed.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
Alejandro Forner et al.
HEPATOLOGY (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tutorial in biostatistics: Competing risks and multi-state models
H. Putter et al.
STATISTICS IN MEDICINE (2007)
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
Vera Rebmann et al.
CLINICAL IMMUNOLOGY (2007)
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
Josep M. Llovet et al.
GASTROENTEROLOGY (2006)
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
Alessandra Gennari et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker
Nola Hylton
JOURNAL OF CLINICAL ONCOLOGY (2006)
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
JS Lee et al.
NATURE MEDICINE (2006)
Prospective validation of the Barcelona Clinic Liver Cancer staging system
U Cillo et al.
JOURNAL OF HEPATOLOGY (2006)
Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review
A Colli et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Deaths on the liver transplant waiting list: An analysis of competing risks
WR Kim et al.
HEPATOLOGY (2006)
Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials
P. M. Lopez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
G D'Amico et al.
JOURNAL OF HEPATOLOGY (2006)
The progress and promise of molecular imaging probes in oncologic drug development
GJ Kelloff et al.
CLINICAL CANCER RESEARCH (2005)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase II designs in cancer clinical trials: Current status and future directions
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Resection and liver transplantation for hepatocellular carcinoma
JM Llovet et al.
SEMINARS IN LIVER DISEASE (2005)
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort
JA Marrero et al.
HEPATOLOGY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation
JY Chien et al.
AAPS JOURNAL (2005)
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance
A Sangiovanni et al.
GASTROENTEROLOGY (2004)
Hazard ratio in clinical trials
SL Spruance et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma
M Sala et al.
HEPATOLOGY (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Stopping clinical trials by design
J Whitehead
NATURE REVIEWS DRUG DISCOVERY (2004)
Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18
JM Blazeby et al.
EUROPEAN JOURNAL OF CANCER (2004)
Molecular imaging of hepatocellular carcinoma
AM Gharib et al.
GASTROENTEROLOGY (2004)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
Risk factors contributing to early and date phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
H Imamura et al.
JOURNAL OF HEPATOLOGY (2003)
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:: a randomised controlled trial
JM Llovet et al.
LANCET (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
CM Lo et al.
HEPATOLOGY (2002)
Measuring health-related quality of life in patients with hepatobiliary cancers: The functional assessment of cancer therapy-hepatobiliary questionnaire
N Heffernan et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Simplified staging for hepatocellular carcinoma
JN Vauthey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the Liver Italian Program staging system - A study based on 926 patients
TWT Leung et al.
CANCER (2002)
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference
J Bruix et al.
JOURNAL OF HEPATOLOGY (2001)
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
D Moher et al.
LANCET (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A model to predict survival in patients with end-stage liver disease
PS Kamath et al.
HEPATOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma
YJ Chen et al.
GASTROENTEROLOGY (2000)
Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival
E Villa et al.
HEPATOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
